These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 31495691)

  • 1. The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis.
    Rabgay K; Waranuch N; Chaiyakunapruk N; Sawangjit R; Ingkaninan K; Dilokthornsakul P
    J Am Pharm Assoc (2003); 2020; 60(1):225-234.e6. PubMed ID: 31495691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies].
    Petzke F; Enax-Krumova EK; Häuser W
    Schmerz; 2016 Feb; 30(1):62-88. PubMed ID: 26830780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, tolerability and safety of cannabis-based medicines for cancer pain : A systematic review with meta-analysis of randomised controlled trials.
    Häuser W; Welsch P; Klose P; Radbruch L; Fitzcharles MA
    Schmerz; 2019 Oct; 33(5):424-436. PubMed ID: 31073761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research.
    Schoedel KA; Harrison SJ
    Curr Pharm Des; 2012; 18(32):5008-14. PubMed ID: 22716155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabis-Based Products for Chronic Pain : A Systematic Review.
    McDonagh MS; Morasco BJ; Wagner J; Ahmed AY; Fu R; Kansagara D; Chou R
    Ann Intern Med; 2022 Aug; 175(8):1143-1153. PubMed ID: 35667066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain.
    Überall MA
    J Pain Res; 2020; 13():399-410. PubMed ID: 32104061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
    Karschner EL; Darwin WD; Goodwin RS; Wright S; Huestis MA
    Clin Chem; 2011 Jan; 57(1):66-75. PubMed ID: 21078841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis.
    Freeman TP; Craft S; Wilson J; Stylianou S; ElSohly M; Di Forti M; Lynskey MT
    Addiction; 2021 May; 116(5):1000-1010. PubMed ID: 33160291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
    Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
    Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations.
    Moore CF; Weerts EM
    Psychopharmacology (Berl); 2022 May; 239(5):1397-1408. PubMed ID: 34652500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis.
    Velayudhan L; McGoohan K; Bhattacharyya S
    PLoS Med; 2021 Mar; 18(3):e1003524. PubMed ID: 33780450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Action and Pharmacokinetics of Cannabis.
    Chayasirisobhon S
    Perm J; 2020 Dec; 25():1-3. PubMed ID: 33635755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review.
    Motaghi E; Ghasemi-Pirbaluti M; Rashidi M; Alasvand M; Di Ciano P; Bozorgi H
    Eur J Clin Pharmacol; 2023 Mar; 79(3):371-381. PubMed ID: 36700997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis.
    Johal H; Devji T; Chang Y; Simone J; Vannabouathong C; Bhandari M
    Clin Med Insights Arthritis Musculoskelet Disord; 2020; 13():1179544120906461. PubMed ID: 32127750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Aviram J; Samuelly-Leichtag G
    Pain Physician; 2017 Sep; 20(6):E755-E796. PubMed ID: 28934780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabis; adverse effects from an oromucosal spray.
    Scully C
    Br Dent J; 2007 Sep; 203(6):E12; discussion 336-7. PubMed ID: 17703180
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.